寧波華翔(002048.SZ)擬定增募資不超23.13億元 峯梅實業全額認購
格隆匯2月8日丨寧波華翔(002048.SZ)披露2021年度非公開發行A股股票預案,此次非公開發行募集資金總額為不超過約23.13億元(含此數),扣除相關發行費用後的募集資金淨額,擬用於補充流動資金。
此次非公開發行股票數量為不超過約1.88億股(含此數),未超過此次發行前公司總股本的30%,最終發行數量以中國證監會核准發行的股票數量為準。
此次非公開發行股票的發行對象為公司實際控制人周曉峯控制的寧波峯梅實業有限公司。發行對象通過現金方式認購此次非公開發行的全部股票。峯梅實業承諾其所認購的股份自此次非公開完成之日起36個月內不得轉讓。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.